Skip to main content
SpringerLink
Log in

Tibotec warns of hepatotoxicity with darunavir

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Health Canada.Health Canada Endorsed Important Safety Information on PREZISTA (darunavir). Media Release: 12 May 2008. Available from: URL: http://www.hc-sc.gc.ca

  2. Health Canada.PUBLIC COMMUNICATION Health Canada Endorsed Important Safety Information on PREZISTA (darunavir). Media Release: 12 May 2008. Available from: URL: http://www.hc.sc.ga.ca

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tibotec warns of hepatotoxicity with darunavir. React. Wkly. 1203, 2 (2008). https://doi.org/10.2165/00128415-200812030-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-200812030-00002

Keywords

Search

Navigation